[PPD, PHA and Su-PS skin tests in genitourinary malignancies].

Area of Science:

• Immunology
• Oncology
• Clinical Medicine

Context:

• Urogenital malignancies represent a significant global health burden.
• Assessing cellular immune status is crucial for understanding cancer patient prognosis.
• Skin tests like PPD, PHA, and Su-PS evaluate delayed-type hypersensitivity responses.

Purpose:

• To investigate the correlation between cellular immune responses, assessed via skin tests, and the clinical course of urogenital malignancy patients.
• To determine the prognostic value of purified protein derivative (PPD) skin tests in relation to survival and tumor stage.

Summary:

• A study of 152 urogenital malignancy patients analyzed skin test results (PPD, PHA, Su-PS) against clinical outcomes.
• Positive PPD skin test responses were significantly associated with higher survival rates (P < 0.005).
• In renal and bladder tumors, positive PPD responses were more frequent in earlier stages (Stage I/low stage) compared to advanced stages (Stage IV/high stage) (P < 0.05).

Impact:

• Skin test reactivity, particularly to PPD, serves as a significant prognostic indicator in urogenital cancers.
• Changes in skin test responses during the observation period may reflect disease progression or treatment response.
• These findings highlight the potential utility of immune status assessment for patient management and outcome prediction.